REFILE-TABLE-Chugai Pharm -6-MTH group results (IFRS)

Thu Jul 25, 2013 3:27am EDT

Related Topics

(Adds company forecast)
Jul 25 (Reuters)- 
              Chugai Pharmaceutical Co Ltd 
     (in billions of yen unless specified) 
                   6 months ended      6 months ended       Year to 
                  Jun 30, 2013        Jun 30, 2012     Dec 31, 2013 
                     LATEST             YEAR-AGO          COMPANY   
                     RESULTS             RESULT          FORECAST   
  Sales              201.02              185.45            416.00           
                   (+8.4 pct)                            (+7.6 pct)            
  Operating           38.12               36.41         77.50            
                   (+4.7 pct)                            (+2.5 pct)           
  Pretax              36.95               35.16                     
                   (+5.1 pct)                                       
  Net                 24.75               21.63                     
                   (+14.4 pct)                                      
  EPS Basic         45.46 yen           39.75 yen        92.57 yen 
    (+8.1 pct)           
  EPS Diluted       45.41 yen           39.73 yen                   
  Ann Div                               40.00 yen        45.00 yen  
  -Q2 Div           22.00 yen           20.00 yen                   
  -Q4 Div                               20.00 yen        23.00 yen   
  NOTE - Chugai Pharmaceutical Co Ltd is a major manufacturer of prescription medicines. 
  (Figures are reported based on international accounting rules (IFRS).) 
  If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half 
  dividend and Q4 to the second-half dividend announced before a new corporate law in 
  2006 allowed companies to pay and report dividends on a quarterly basis.
  *Net - represents Net profit attributable to owners of the parent company. 
  For latest earnings estimates made by Toyo Keizai, please double click on. 

 (Reporting By Kuniko Nishikubo)
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.